Navigation Links
Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
Date:6/4/2010

pretreated group of patients with myeloma, with no overlapping toxicities with the treatment triplet.  We look forward to further study of this important carfilzomib-based combination regimen in the upcoming international Phase 3 trial."

Additional Phase 1b Trial Results

The study was designed to evaluate the safety, maximum tolerated or maximum per-protocol doses, and efficacy of carfilzomib in combination with lenalidomide and low-dose dexamethasone.  Forty patients were enrolled in the dose-escalation portion of this study (cohorts 1-6).  Doses were escalated from 15mg/m2 carfilzomib and 10mg lenalidomide to the maximum per-protocol doses of 27 mg/m2 carfilzomib and 25mg lenalidomide.  A total of fifty-two patients received the maximum per-protocol doses, including eight patients in cohort 6 and forty-four patients in the expansion cohort.  All patients enrolled in the study received 40mg low dose dexamethasone.

Of the 84 patients in the trial, 79 percent had received more than two prior treatment regimens for myeloma with 74 percent of the patients having received prior bortezomib, 87 percent prior immunomodulatory drug therapy (67 percent prior lenalidomide and 44 percent prior thalidomide), and 98 percent prior steroids.

Side effects were clinically manageable and generally consistent with those typically seen with the agents that were combined with carfilzomib.  Grade 3/4 adverse events included neutropenia (23 percent), thrombocytopenia (18 percent), anemia (12 percent), and hyperglycemia (5 percent).  The triple combination regimen was well tolerated and prolonged administration (14-23 months) without interruption was possible, allowing for durable disease control. Initial responses typically occurred within the first cycle, with many patients showing even greater improvement over the subs
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
3. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
4. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
5. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
6. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
7. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
8. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
9. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
10. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
11. ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Children aren,t the only segment of our ... disease. The Centers for Disease Control and Prevention ... many adults are not following this advice. ... and the American Lung Association in partnership with ... disease, to talk with their health care provider ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, ... http://www.reportlinker.com/p0652514/Wireless-Opportunities-in-Healthcare-The-Market-for-Bluetooth-RFID-Zigbee-UWB-WWAN-WMAN-WLAN-and-other-technologies.html Kalorama Information,s ... Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that ... device market will expand through 2023 as ... fibrillation (AF). The increasing acceptance of ablation ... will spur adoption of premium-priced products designed ... loop diagnostic catheters, cryoablation catheters and contact ...
Breaking Medicine Technology:American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... April 18, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has accepted for review the ... the treatment of the neovascular form of age-related macular ... request for priority review of its BLA.  A Priority ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: ... meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. ... The meeting will take place at the Hyatt Regency Hotel in ... PDL pioneered the humanization of monoclonal antibodies and, ...
Cached Medicine Technology:FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
(Date:8/20/2014)... In less than a week the airwaves ... to fight muscle related disease. Helping the huge telethon ... brands through their cause-related marketing heft. With their help ... nearly $60 million. , But for small self-serve business ... cause-related marketing remains decidedly local and, although the money ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... Jacksonville, FL (PRWEB) August 20, 2014 ... Continuing Education Standards (IBCCES) , an organization recognizing ... area of autism, has announced that with a ... in working with people on the Autism Spectrum ... commitment to providing quality care. This, in turn, ...
(Date:8/20/2014)... 2014 (HealthDay News) -- A group representing U.S. obstetricians ... flu shot. According to the American College of ... years have upheld the safety and effectiveness of flu ... infectious and can be particularly dangerous to pregnant women, ... complications," Dr. Laura Riley, chair of the college,s Immunization ...
(Date:8/20/2014)... the immune system is defective in people suffering from irritable ... ongoing issues with pain. , The research the first ... to explain why some painkillers may not offer satisfactory relief ... 10% of the community. There are different forms of ... often has the greatest impact on sufferers, quality of life. ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... leader in soft-cloth nasal CPAP masks, announces the new Zzzephyr ... comfortably over the patient,s nose. The lightweight seal reduces air ... Obstructive Sleep Apnea patients. , The SleepWeaver ADVANCE with Zzzephyr ... at the Medtrade Fall Show in Atlanta, Georgia, October 12 ...
... Calif., Oct. 26 Ingenuity Systems, the leading provider ... it has developed a new gene expression workflow with ... and the Applied Biosystems SOLiD(TM) System and TaqMan® Gene ... for researchers to analyze and understand the transcriptome of ...
... particularly younger women, experienced larger improvements in hospital mortality ... study published in the Oct. 26, 2009 issue of ... decade several studies showed that younger women, but not ... hospital after MI than age-matched men. A team of ...
... The topical application ... and absorption throughout the surface of the skin and scalp. A new line of naturally ... for a variety of topical conditions affecting the skin, scalp and feet. , ... Schenectady, NY (PRWEB) October 26, 2009 -- ...
... ... announce it has been honored with the BayCare Quality Award for the team,s project ... patient successes including follow through on outpatient office visits, 30-day readmission rates, and A1c ... ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... modification and Lorcaserin for Overweight and Obesity Management) ... weight loss, improved markers of cardiovascular risk and ... or suicidal ideation. Additional subgroup analyses showed that ...
Cached Medicine News:Health News:Circadiance Launches NEW Zzzephyr Seal(TM) for Its SleepWeaver(TM) ADVANCE Mask - Now Available in Three Colors 2Health News:Ingenuity Systems Enhances Workflow for Experimental Transcriptome Analysis in Single Cells 2Health News:Survival after heart attack improves in younger women 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 2Health News:Caffeinated Cayenne Pepper Body Sprays Relieve Common Skin and Scalp Problems 3Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 2Health News:IN Compass Health's Hospitalist Team at Morton Plant wins first BayCare Quality Award 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 2Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 3Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 4Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 5Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 6Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 7Health News:Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation 8
MBP's equivalent to the "Universal Yellow" tip, this 200 ul tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... easy way to order tips. Each box contains ... D10mL, which contains 200 tips (4 bags of ... Packs of 200 tips per pack. Bulk Packs ... easily be opened for quick access to Gilsons ...
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
Medicine Products: